secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001193125-23-283693
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics appoints Cameron Turtle CEO; name change to Spyre, ticker SYRE effective Nov 28
--------------------------------------------------------------------------------

- Cameron Turtle, previously COO, appointed CEO and director; $625K base, 55% target bonus, option for 374K shares at $10.39.
- Name change from Aeglea BioTherapeutics to Spyre Therapeutics; ticker changes from AGLE to SYRE effective Nov 28, 2023.
- Directors Ivana Magovčević-Liebisch and Hunter Smith resign; Laurie Stelzer (chair audit) and Jeffrey Albers appointed to board.
- Pipeline on track: SPY001 (anti-α4β7) FIH H1 2024; SPY002 (anti-TL1A) FIH H2 2024; SPY003 (anti-IL-23) IND 2025; cash $205M into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/d610145d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-283693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer